Clinical experience of antibodies to interferon-alpha during treatment of chronic myeloid leukemia.
Interferon-alpha (IFN-alpha) remains the only viable alternative to bone marrow transplantation for patients with chronic myeloid leukemia (CML) and is the treatment of choice in many circumstances. IFN-alpha can induce hematologic remissions in most patients with CML and suppresses the Philadelphia chromosome-positive cell clone in 30%-40% of hematologically responsive patients. IFN-alpha can also prolong the length of the chronic disease phase and survival time in patients who achieve a karyotypic response. A third of patients, however, never respond to IFN-alpha, and a proportion of the initial responders will later become resistant. It has been suggested that the induction of anti-IFN-alpha antibodies might be one of the reasons for resistance to IFN-alpha. It is difficult to evaluate the factors that influence antibody induction and the effects of these antibodies on clinical results. The source of IFN-alpha product, trial design, and differences in the sensitivity of the assays used to measure antibodies are all factors that need to be considered.
Russo
D
D
Department of Medical and Morphological Research, Udine University Hospital, Italy.
Candoni
A
A
Grattoni
R
R
D000937:Antigen-Antibody Reactions; D006801:Humans; D007124:Immunoenzyme Techniques; D015592:Immunoradiometric Assay; D007370:Interferon Type I / Q000737:chemistry / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins